Bronchodilator safety in chronic obstructive pulmonary disease-reply

Affiliations

¹ Division of Respirology, Department of Medicine, University Health Network, Toronto, Ontario, Canada3Institute for Clinical Evaluative Sciences, Toronto, Ontario, Canada4Division of Respirology, Department of Medicine, University of Toronto, Toronto, Onta.
² Institute for Clinical Evaluative Sciences, Toronto, Ontario, Canada.
³ Division of Respirology, Department of Medicine, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada3Institute for Clinical Evaluative Sciences, Toronto, Ontario, Canada4Division of Respirology, Department of Medicine, University of Toronto, Toron.

Comment

Matthew B Stanbrook et al. JAMA Intern Med. 2014 Apr.

. 2014 Apr;174(4):648.

doi: 10.1001/jamainternmed.2013.12684.

¹ Division of Respirology, Department of Medicine, University Health Network, Toronto, Ontario, Canada3Institute for Clinical Evaluative Sciences, Toronto, Ontario, Canada4Division of Respirology, Department of Medicine, University of Toronto, Toronto, Onta.
² Institute for Clinical Evaluative Sciences, Toronto, Ontario, Canada.
³ Division of Respirology, Department of Medicine, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada3Institute for Clinical Evaluative Sciences, Toronto, Ontario, Canada4Division of Respirology, Department of Medicine, University of Toronto, Toron.

No abstract available

Comment on

Cardiovascular safety of inhaled long-acting bronchodilators in individuals with chronic obstructive pulmonary disease.
Gershon A, Croxford R, Calzavara A, To T, Stanbrook MB, Upshur R, Stukel TA. Gershon A, et al. JAMA Intern Med. 2013 Jul 8;173(13):1175-85. doi: 10.1001/jamainternmed.2013.1016. JAMA Intern Med. 2013. PMID: 23689820
Bronchodilator safety in chronic obstructive pulmonary disease: time to focus?
van Dijk WD, Käyser SC. van Dijk WD, et al. JAMA Intern Med. 2014 Apr;174(4):647. doi: 10.1001/jamainternmed.2013.12708. JAMA Intern Med. 2014. PMID: 24711198 No abstract available.